Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Eric Bjerkholt Sells 5,000 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 5,000 shares of the stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $93.82, for a total transaction of $469,100.00. Following the sale, the chief financial officer directly owned 44,788 shares of the company’s stock, valued at approximately $4,202,010.16. This represents a 10.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Bjerkholt also recently made the following trade(s):

• On Monday, March 16th, Eric Bjerkholt sold 7,287 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $91.98, for a total transaction of $670,258.26.

Mirum Pharmaceuticals Stock Up 2.0%

MIRM stock opened at $95.48 on Wednesday. Mirum Pharmaceuticals, Inc. has a 12 month low of $47.15 and a 12 month high of $114.99. The firm has a market cap of $5.82 billion, a PE ratio of -7.02 and a beta of 0.50. The firm has a 50 day simple moving average of $97.53 and a 200 day simple moving average of $90.70. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The business had revenue of $159.88 million for the quarter, compared to analyst estimates of $148.21 million. During the same period in the prior year, the company earned ($0.30) earnings per share. The firm’s revenue for the quarter was up 43.3% on a year-over-year basis. Equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on MIRM shares. Citigroup started coverage on shares of Mirum Pharmaceuticals in a research note on Tuesday, June 2nd. They set a “buy” rating and a $145.00 target price for the company. Evercore restated an “outperform” rating and set a $138.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Wall Street Zen lowered shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Royal Bank Of Canada boosted their price target on shares of Mirum Pharmaceuticals from $128.00 to $142.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Finally, Raymond James Financial restated a “strong-buy” rating and set a $165.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $137.64.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Large investors have recently made changes to their positions in the company. Cullen Frost Bankers Inc. acquired a new stake in shares of Mirum Pharmaceuticals during the fourth quarter valued at approximately $30,000. Eurizon Capital SGR S.p.A. acquired a new position in Mirum Pharmaceuticals in the 4th quarter valued at approximately $32,000. CIBC Private Wealth Group LLC acquired a new position in Mirum Pharmaceuticals in the 4th quarter valued at approximately $32,000. MCF Advisors LLC increased its stake in Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares during the period. Finally, Quantbot Technologies LP acquired a new position in Mirum Pharmaceuticals in the 3rd quarter valued at approximately $33,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.